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ABSTRACT
Objective: We investigated the expression of Extended Spectrum β-Lactamases (ESBLs), AmpC β lactamases and Car-
bapenemases in extraintestinal pathogenic Escherichia coli (ExPEC) isolates and correlated with treatment and outcome 
of the patients. 
Methods: Three hundred ExPEC infected patients were included in the study. Demographic data, antibiogram, treat-
ment and outcome were collected. Production of ESBLs was detected by combination disk method; AmpC was detected 
by AmpC disk test. Carbapenemase production was detected by disk diffusion and confirmed by modified Hodge test. 
Identification of metallo- β-lactamase (MBL) activity was performed by the carbapenem-EDTA combined disk method 
and MBL E-test. 
Results: Out of 300 E. coli isolates, 212 (71%) were ESBL producers. AmpC β lactamase production was seen in 95 (32%) 
isolates; 16 (17%) isolates were pure AmpC producers whereas 79 (83%) were ESBL co-producers. Twenty nine (9.5%) 
isolates were carbapenemase producers of which 15 (5%) were MBL producers. For treatment, most widely prescribed 
antibiotics were β-lactam+β-lactamase inhibitor combinations (39%). Sixty seven percent patients improved; relapse/
re-infection was seen in 18% of patients and 11% patients expired. Increased mortality was seen in patients with blood 
stream infection and more number of relapses was seen in urinary tract infection.
Conclusion: ExPEC producing ESBL or AmpC along with carbapenemases are particularly challenging for clinicians and 
are a major threat worldwide. Early use of appropriate antibiotics like β-lactam+β-lactamase inhibitor combinations will 
probably reduce complications in these patients.
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Ekstra intestinal Escherichia coli izolatlarından GSBL, MBL ve AmpC β laktamazların 
salınımı: Tedavi ve klinik sonuçlarla uyumu
ÖZET
Amaç: Ekstra intestinal patojenik Escherichia coli (EİPEC) izolatlarından salınan GSBL, AmpC β laktamazlar ve Karbape-
nemazların salınımını ve bu hastaların tedavisi ve klinik gidişle ilişkisini araştırdık.
Yöntemler: Çalışmaya 300 EİPEC ile enfekte hasta alındı. Demografik veriler, antibiyogram, tedavisi ve sonuçları top-
landı. GSBL üretimi kombine disk metodu ve AmpC üretimi AmpC-disk testi ile tespit edildi. Karbapenemaz salınımına 
modifiye Hodge testi ile doğrulanmış disk diffüzyonla bakıldı. Metallo-β-laktamaz (MBL) aktivitesi karbapenem-EDTA 
kombine disk metodu ve MBL E-test ile çalışıldı. 
Bulgular: Üç yüz E. coli izolatının 212’si (% 71) GSBL pozitif idi. AmpC β laktamaz üretimi 95 (% 32) görüldü; izolatların 
16’sı (% 17) saf AmpC üretirken, 79’u (% 83) GSBL ile beraberdi. Karbapenemaz üreten yirmi dokuz (% 9,5) izolatın 15’i 
(% 5) MBL üretiyordu. Tedavi için, en yaygın olarak reçete edilen antibiyotikler β-laktam + β-laktamaz inhibitör kombi-
nasyonları (% 39) idi. Hastaların % 67’i iyileşti; nüks/yeni enfeksiyon hastaların % 18’inde görülürken % 11 hasta da öldü. 
Kan dolaşımı enfeksiyonu olan ve sık nüks eden idrar yolu enfeksiyonlarında mortalite daha yüksekti.
Sonuç: Karbepenamazlarla birlikte GSBL veya AMPC üreten EİPEC özellikle klinisyenler için dünya çapında büyük bir 
tehdit oluşturmaktadır β laktam + β laktamaz inhibitör kombinasyonu gibi uygun antibiyotiklerin erken kullanımı muh-
temelen bu hastalarda komplikasyonları azaltacaktır. 
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INTRODUCTION
Infection with extraintestinal pathogenic Escherichia 
coli (ExPEC) is an important public health problem 
worldwide. They are responsible for urinary tract, 
intra-abdominal and soft tissue infections, meningi-
tis, pneumonia and osteomyelitis and are often as-
sociated with bacteremia.1 The prevalence of multi-
drug-resistant ExPEC has increased progressively 
over the past few years, and infections with bacte-
rial strains producing carbapenemases, AmpC beta 
lactamases and/or extended spectrum beta-lacta-
mases are of particular concern.2,3 For several years 
carbapenemases were highly effective against bac-
teria that exhibited resistance to extended spectrum 
cephalosporins (e.g. Ceftazidime and Cefepime), 
including ESBL and AmpC producers. However, as 
carbapenemases began to emerge worldwide, the 
effectiveness of this last-line antibiotic class was 
challenged.4
There is insufficient data regarding expression 
of ESBL, AmpC and metallo-β-lactamases (MBL) 
by E. coli strains causing extraintestinal infections 
in India. Hence, the present study was undertaken 
to find out the prevalence of ESBL, AmpC and MBL 
production among ExPEC isolates in a tertiary care 
hospital and to co-relate such infections with treat-
ment and clinical outcome.
METHODS
Participants and clinical isolates: The study was con-
ducted during the period from August 2010 to Janu-
ary 2012, from patients of the tertiary care hospitals 
attached to Kasturba Medical College, Mangalore, 
India, after obtaining permission from the institution-
al ethical committee. Sample size was determined 
with 55% confidence level and 90% power accord-
ing to earlier study.5 Three hundred strains of E. coli 
were isolated from specimen such as urine, blood, 
wound swab, pus, CSF, ascites fluid and intravas-
cular devices from the study population. Study pop-
ulation included patients of all age groups whose 
clinical samples grew E. coli and excluded subjects 
who had received antimicrobial drugs during past 
one month, who had asymptomatic UTI, polymicro-
bial infections and those who were discharged with-
out treatment. Details of antibiotics used and clinical 
outcome of patients were collected. Samples were 
processed immediately using standard procedures. 
Isolates were identified based on colony morphol-
ogy on Blood agar, MacConkey’s agar, Gram stain-
ing and by standard biochemical tests.5 Blood iso-
lates were identified using automated biochemical 
system Vitek 2 (bioMerieux).
Antimicrobial susceptibility testing
Antibiotic susceptibility testing was done by the 
modified Kirby-Bauer disk diffusion method in ac-
cordance with CLSI guidelines.6 The antibiotic disks 
(HiMedia, Mumbai, India) used were Ampicillin (10 
µg), Piperacillin (10 µg), Piperacillin/Tazobactam 
(100/10 µg), Ceftriaxone (30 µg), Cefotaxime (30 
µg), Ciprofloxacin (5 µg), Norfloxacin (10 µg), Ami-
kacin (30 µg), Gentamicin (10 µg), Cotrimoxazole 
(1.25/23.75 µg), Cefoperazone + Sulbactam (75/30 
µg), Imepenem (IPM; 10 µg), Meropenem (MRP; 10 
µg) and Etrapenem (ETP; 10 µg).
Screening for ESBL production
Isolates which were resistant to third generation 
cephalosporins were tested for ESBL production 
by combination disk method using cefotaxime (30 
µg), cefotaxime/clavulanic acid (10 µg), ceftazidime 
(30 µg) and ceftazidime/clavulanic acid (10 µg). A 
≥5mm  increase  in  diameter  of  inhibition  zone  of 
cephalosporin+clavulanate disc when compared 
to cephalosporin disc alone was interpreted as evi-
dence of ESBL production.6
Detection of AmpC production
Isolates were tested for AmpC enzyme production 
by AmpC disk test.7 Briefly, a suspension of ATCC 
E. coli 25922 standardized to 0.5 McFarland was 
inoculated  on  the  surface  of  Mueller-Hinton  agar 
(MHA) plate. A 30 µg cefoxitin disk were placed on 
the inoculated surface of the agar. 
Detection of carbapenemase production
Plates of MHA were inoculated with standardized 
suspensions of the test strains. A sat of discs of 
IPM, MRP and ETP (10 µg each) were applied to 
the surface of the agar, plates were incubated over-
night at 35°C aerobically, and diameters of zone of 
inhibition  (≥23  mm  indicated  sensitivity,  20  to  22 
mm indicated intermediate resistance and ≤19 mm 
indicated resistance) were recorded. Carbapene-
mase production was further confirmed by modified 
Hodge test (MHT).6
Detection of metallo- β- lactamase producers 
Identification  of  MBL  activity  was  performed  by 
two methods: a carbapenem-EDTA combined disk 
method and MBL E-test (HiMedia, India).8 A known 
MBL producing isolate was used as positive con-
trol for all tests. Combined disk test: The IPM-EDTA 
combined disk method was performed as described 
previously.8 MBL E-test (IPM-EDTA E-test, HiMe-
dia) was used to detect MBL production and MIC of Chakraborty A, et al. Drug resistant ExPEC infections and clinical outcome 152
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IPM to the test isolates and was performed by E-test 
according to the recommendations of the manufac-
turer.8
Imipenem MIC
E-Strips were used for determination MIC of Imi-
penem.8 Briefly, test isolates were inoculated in a 
Mueller Hinton Agar plate. Strips were placed at a 
desired position on agar plate swabbed with test 
culture. The plates were incubated overnight at 37°C 
aerobically.  Interpretation  of  MIC  values:  <8  µg/
ml=Sensitive; 8-16 µg/ml=Intermediate resistance; 
>16 µg/ml=Resistant.
Statistical analysis
Chi-square test was used to find association be-
tween ESBL, AmpC and carbapenemase produc-
ers. Analysis was performed using statistical pack-
age SPSS 17.0 (SPSS, USA).
RESULTS
A total 300 patients with extraintestinal E. coli infec-
tion were included in this study. These included 159 
(53%) cases of UTI, 77 (25.6%) with bacteremia, 40 
(13.3%) with wound infection, 19 (6.3%) with pneu-
monia, 3 (1%) intravascular device infection and 2 
(0.6%) with meningitis (Table 1). One hundred forty 
three patients were from medical unit, 44 from sur-
gical, 43 from urology, 20 from oncology, 20 from 
gastroenterology, 13 from OBG, 12 from orthope-
dics and 5 from pediatrics units. 
Demographic data of patients: Of the 300 pa-
tients, 163 (54%) were males and 137 (46%) were 
females with the age group of <1= 4 (1.3%), 1-18= 
8 (2.6%), 18-44=71 (23.6%), 45-59=87 (29%) and 
>60=130 (43%). Majority were Community acquired 
infections, 267 (89%) and 33 (11%) were hospital 
acquired infections (Table 1).
Type of ExPEC strains ESBL producers,
n=212 (%)
AmpC producers,
n=95 (%)
Carbapenemase producers,
n=29 (%)
Type of Infection
UTI 109 (51.5) 48 (50.5) 19 (65.5)
Bacteremia 56 (26.5) 22 (23) 4 (14)
Wound Infection 29 (14) 15 (16) 2 (7)
Pneumonia 14 (6) 7 (7) 2 (7)
IVD Infection 2 (1) 1 (1) 0
Meningitis 2 (1) 2 (2) 2 (7)
Age Group (Years)
< 1 3 (1.5) 1 (1) 1 (3.5)
1 - 18 6 (3) 4 (4) 0
19 - 44 48 (23) 26 (27) 8 (27.5)
45 - 59 63 (30) 31 (33) 12 (41)
> 60 92 (43) 33 (35) 8 (27.5)
Gender
Male 119 (56) 52 (55) 19 (65.5)
Female 93 (44) 43 (45) 10 (34.5)
UTI=Urinary tract infection, IVD=Intravascular devices
Table 1. Demo-
graphic detailes 
of the patients 
infected with 
ESBL, AmpC 
and Carbapen-
emase produc-
ing extra-intesti-
nal E. coli.
ESBL producers
Of the 300 E. coli  isolates,  212  were  confirmed 
ESBL producers by double disk diffusion assay, in-
dicating a prevalence of 70.6% (212/300). Of these, 
97  (46%)  strains  of  ESBL  producers  were  from 
medical wards (Table 2).The clinical sites of isola-
tion are summarized in table 1. For 185 patients the 
ESBL producing strains were isolated in the first 24 
h after admission. The remaining patients present-
ed with infection from 5 days up to 3 months after 
admission, suggesting that these were hospital ac-
quired infections. The analysis of drug resistance 
pattern showed that all ESBL producers were more 
frequent co-resistance to other non-beta lactam 
classes of antibiotics (Table 2).Chakraborty A, et al. Drug resistant ExPEC infections and clinical outcome 153
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Type of ExPEC strains
ESBL producers,
n=212 (%)
AmpC producers.
n=95 (%)
Carbapenemase 
producers, n=29 (%)
Medicine 97 (46) 42 (44) 12 (46.5)
Surgery 30 (14) 14 (15) 5 (17)
Urology 31 (15) 12 (13) 7 (24)
Gastroenterology 17 (8) 7 (7) 0
Oncology 17 (8) 7 (7) 2 (7)
OBG 10 (4) 9 (9) 1 (3.5)
Orthopedics 6 (3) 3 (3) 1 (3.5)
Pediatric 4 (2) 1 (1) 1 (3.5)
Community acquired 185 (87) 75 (79) 22 (22)
Hospital acquired 27 (13) 20 (21) 7 (24)
Resistance to non-β lactams
Fluoroquinolones
Ciprofloxacin 167 (79) 73 (77) 28 (96)
Norfloxacin 88 (41.5) 41 (43) 17 (59)
Sulfonamides
Co-trimoxazole 88 (41.5) 43 (45) 16 (55)
Aminoglycosides
Amikacin 41 (19) 24 (25) 16 (55)
Gentamicin 122 (57.5) 55 (58) 19 (65)
Note: Several strains of ExPEC produce multiple enzymes, data of which is not shown above.
Figure 1. Detection and determination of minimum inhibi-
tory concentration (MIC) to Imipenem by ExPEC strains.
Table 2. Prevalence 
of ESBL,AmpC & 
Carbapenemase pro-
ducing E.coli causing 
extra-intestinal infec-
tion.
AmpC producers: AmpC β lactamase produc-
tion was observed in 95 (32%) isolates by the AmpC 
disk test. Sixteen (17%) isolates were pure AmpC 
producers  whereas  79(83%)  isolates  were  ESBL 
co-producers. Isolation wards, clinical sites, age 
group and drug resistance pattern to other non β 
lactam classes of antibiotics by the AmpC produc-
ing isolates are summarized in table 1. There is a 
significant difference (p<0.05) between ESBL and 
AmpC producers.
Carbapenemase producers
In this study, 29 (9.5%) isolates of E. coli were car-
bapenemase producers by disk diffusion test and 
modified Hodge test (Table 1). The isolates were 
further evaluated phenotypically for presence of 
metallo β- lactamase (MBL), using the metal che-
lating agent EDTA. Fifteen (5%) isolates were MBL 
positive by both combined disk tests and MBL E-
test (Figure 1).Chakraborty A, et al. Drug resistant ExPEC infections and clinical outcome 154
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Imipenem resistance
Of the 300 strains of ExPEC, 18 were found to be 
resistant to Imipenem (MIC of > 16 µg/ml) as de-
tected by the E-test (Table 3). Eighty strains, which 
had MIC of 8 - 16 µg/ml were found to demonstrate 
intermediate resistance to imipenem. It was ob-
served that the hospital strains of E. coli showed 
significantly higher resistance (p<0.05) to imipenem 
than community acquired strains (Table 3).
Table 3. Susceptibility patterns of ExPEC to Imipenem:
Type of Infection
Source Susceptibility UTI Wound Bacteremia Pneumonia IVD infection Meningitis Total (%)
Sensitive 57 10 37 6 0 0 110
Community
acquired Intermediate 68 22 34 11 1 2 138
Resistant 13* 0 4 0 0 0 17
Total no. of community
acquired strains
138 32 75 17 1 2 265
Sensitive 3 3 0 0 0 0 6
Hospital
acquired
Intermediate 12 4 1 2 2 2 23
Resistant 5* 1 0 0 0 0 6
Total no. of hospital
acquired strains 20 8 1 2 2 2 35
Total no. of strains 158 40 76 19 3 4 300
# Interpretation of MIC values, <8µg/ml = Sensitive; 8 - 16µg/ml = Intermediate resistance; >16µg/ml = Resistant; *No. 
of resistant strains of ExPEC from UTI were significantly higher (P< 0.05) in hospital acquired infections when com-
pared to community acquired strains.
Treatment & Outcome
The most widely prescribed antibiotics were β lac-
tam + β lactamase inhibitors, cephalosporins, and 
carbapenems. Of our study population, maximum 
number of patients (67%) recovered with appropri-
ate antibiotic treatment. Relapses and re-infections 
were seen in 18% patients and in 11% of patients 
the primary cause of death was ExPEC infection. 
Outcome of ExPEC infection with ESBL, AmpC and 
carbapenemase producers are summarized in Fig-
ure 2.
Figure 2. Outcome of infection 
with ExPEC producing ESBL, 
AmpC and Carbapenemases (Sev-
eral isolates produced multiple en-
zymes, data not shown)
DISCUSSION
Escherichia coli is emerging as an important cause 
of extraintestinal infections in our hospitals. The 
growing increase in the rate of antibiotic resis-
tance of these isolates is a major cause of concern. 
β-lactams have been the mainstay of treatment for 
serious infections, the most active of these being Chakraborty A, et al. Drug resistant ExPEC infections and clinical outcome 155
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carbapenems, which are advocated for use in treat-
ment of infections caused by ESBL producing En-
terobacteriaceae, particularly Escherichia coli and 
Klebsiella pneumoniae.9 Pathogens that produce 
ESBL or AmpC β lactamases along with carbapen-
emases are particularly challenging for clinicians 
and are a major threat worldwide.
Results of our study have shown that extraint-
estinal infection with ESBL producing E. coli of hos-
pitalized patients was 71% in our setting. Other stud-
ies from India have reported 50-70% prevalence of 
ESBL producing among E. coli.5,10 We found most 
of our urine isolates were ESBL producers which 
was common in all age groups. ESBL producing E. 
coli were isolated from infants also. However, ESBL 
isolates were more common in elderly patients and 
from Medical units. Several studies have also re-
ported similar results.11,12
Previous studies have shown that ESBL pro-
ducing organisms were frequently resistant to non 
β-lactam antibiotics such as fluoroquinolones, co-
trimoxazole and aminoglycosides.5,13 In our study 
we found a high degree of resistance to multiple 
classes of antibiotics among ESBL producing iso-
lates. Only carbapenem group of antibiotics were 
the most active (9.5% were resistant) among all an-
timicrobials tested.
In our study population, we found that 31.6% 
of isolates were AmpC producers. Other studies 
from India have reported a 30-50% prevalence rate 
of AmpC production among E. coli.14,15 Seventeen 
percent of these isolates were pure AmpC produc-
ers. Several studies have reported about 8-15% of 
the isolates were pure AmpC producers.14,15 A study 
from Canada has shown that the highest number of 
AmpC producing isolates were from urine samples, 
from elderly patients (>60 years) and from medical 
care units which was similar to our findings.16
Analysis of antibiograms for AmpC producing 
isolates revealed that 95% of strains were resistant 
to amoxicillin-clavulanic acid. In contrast, 43% of 
strains were resistant to piperacillin/tazobactam. 
For extended spectrum cephalosporins, 68% of 
strains  were  resistant  to  ceftazidime  and  92.5% 
were resistant to cefotaxime. Several studies have 
shown that cephalosporin susceptibility screening 
of E. coli isolates with the initial purpose of ESBL 
identification resulted in selection for AmpC produc-
ing strains.17,18 On the basis of our results, we can-
not recommend extended spectrum cephalosporins 
as screening parameters for AmpC, which is similar 
to other findings.19
In our study, 7.5% of the ExPEC isolates were 
carbapenemase producers. Several studies from 
India have shown a prevalence rate of 8-10% of 
enterobacteriaceae isolates being carbapenemase 
producers.20,21 However although only 5% of our 
ExPEC isolates were positive for MBL activity, it is 
alarming as such infections may result in mortality 
or chronic persistence leading to repeated hospital-
ization.
The  problem  with  MBL  producing  isolates  is 
their unrivalled broad-spectrum resistance profile. 
These MBL positive strains are usually resistant to 
β-lactams, aminoglycosides and fluoroquinolones. 
However, they usually remain susceptible to poly-
myxins. No extended survey with a series of hu-
man infections with MBL positive isolates has been 
performed to determine optimal treatment. The only 
alternative may be the therapeutic administration of 
polymyxins, which has recently been shown to be 
efficient for treating multidrug-resistant gram nega-
tive bacilli.22,23 In any case, these molecules should 
not be used in mono-therapy and rapid determina-
tion of MICs of aminoglycosides may help to choose 
an aminoglycoside molecule that may have some 
activity. Clearly, in the absence of novel agents in 
the near future, the spread of MBL producers may 
lead to therapeutic dead ends. 
In our study we found that β lactam + β lac-
tamase inhibitor was considered the most reli-
able class of antibiotics for treatment of infections 
caused by ESBL producing ExPEC while for non 
ESBL producing ExPEC cephalosporins were the 
most prescribed antibiotics. However, for treatment 
of MBL producing ExPEC multiple groups of antibi-
otics was used.
We also found some of our patients improved 
with treatment of antibiotics, which were found to be 
resistant by the modified Kirby-Bauer disk diffusion 
method, and based on this finding, we recommend 
that for MDR isolates, MIC should be performed for 
higher antibiotics to reduce cost of treatment and to 
prevent morbidity. 
Outcome of our study indicates that 67% of 
patients improved with proper antibiotic treatment 
whereas 18% patients developed relapse/re-infec-
tion and 11% of patients expired due to infection 
caused by multi-drug resistant E. coli. Mortality was 
significantly higher for patients with blood stream 
infection, which was comparable to previous stud-
ies.24,25 However, it is difficult to demonstrate attrib-
utable mortality solely to infection without proper 
study design and/or autopsy to provide evidence as 
some patients had other underlying conditions. Chakraborty A, et al. Drug resistant ExPEC infections and clinical outcome 156
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In conclusion, microbiology laboratories must 
be able to detect resistant pathogens in a timely 
manner, especially those that are falsely suscepti-
ble in vitro to drugs that may be considered for ther-
apy of infected patients. Microbiological excellence 
is needed more than ever, and ESBLs, AmpC β lac-
tamases and carbapenemases production should 
be detect accurately. In addition, there should be 
good communication between the microbiologist 
and the health care worker to make better patient 
outcomes, facilitating effective infection control, re-
ducing spread of resistant pathogens and helping 
hospitals to meet accreditation standards. This will 
help in the fight against multidrug resistance ExPEC 
and if corrective measures are not taken, in the ab-
sence of novel agents in the near future, the spread 
of MDR isolates may lead to therapeutic dead ends. 
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